| 2026-08-13 | Presentation | Caribou Corporate Presentation August 2026 |
| 2026-08-13 | Press release | PDF Version |
| 2026-08-13 | Press release | Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update |
| 2026-06-29 | Press release | Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference |
| 2026-06-12 | Presentation | Long term durability data from the vispa-cel ANTLER phase 1 clinical trial, EHA 2026 oral presentation |
| 2026-06-11 | Press release | Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026 |
| 2026-06-11 | Press release | Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) |
| 2026-05-27 | Press release | Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference |
| 2026-05-13 | Press release | Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference |
| 2026-05-12 | Press release | Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology |
| 2026-05-07 | Press release | Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-05-05 | Press release | Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference |
| 2026-03-31 | Press release | Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Al |
| 2026-03-05 | Press release | Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update |
| 2026-03-04 | Presentation | Translational data for vispa-cel ANTLER Phase 1 clinical trial, Tandem Meetings 2026 poster |
| 2026-02-12 | Press release | PDF Version |
| 2026-02-12 | Press release | Caribou Biosciences to Participate in Upcoming Investor Conferences |
| 2026-02-07 | Presentation | Clinical and translational data for CB-011 CaMMouflage Phase 1 clinical trial, Tandem Meetings 2026 presentation |
| 2026-02-04 | Press release | PDF Version |
| 2026-02-04 | Press release | Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR® |
| 2025-12-01 | Press release | PDF Version |
| 2025-12-01 | Press release | Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025 |
| 2025-11-03 | Presentation | Clinical updates for vispa-cel (CB-010) and first clinical data for CB-011, company event 2025 |
| 2025-11-03 | Press release | PDF Version |
| 2025-11-03 | Press release | PDF Version |
| 2025-11-03 | Press release | PDF Version |
| 2025-11-03 | Press release | Caribou Biosciences to Participate in Upcoming Investor Conferences |
| 2025-11-03 | Press release | Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma |
| 2025-11-03 | Press release | Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel |
| 2025-11-02 | Press release | PDF Version |
| 2025-11-02 | Press release | Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lympho |
| 2025-08-25 | Press release | Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference |
| 2025-05-28 | Press release | PDF Version |
| 2025-05-28 | Press release | Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference |
| 2025-05-06 | Press release | Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference |
| 2025-03-10 | Press release | PDF Version |
| 2025-03-10 | Press release | Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
| 2025-02-18 | Press release | PDF Version |
| 2025-02-18 | Press release | Caribou Biosciences to Participate in Upcoming Investor Conferences |
| 2025-01-12 | Press release | PDF Version |